WINDLASNSE22 May 2025

Windlas Biotech Limited has informed the Exchange about Investor Presentation

Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area Dehradun, Uttarakhand 248 110, India Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66, Golf Course Ext. Road, Gurgaon, Haryana 122 001, India Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

May 22, 2025

To Listing / Compliance Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001

To Listing / Compliance Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051

BSE CODE: 543329

NSE SYMBOL: WINDLAS

Dear Sir/ Madam.

Sub: Regulation 30(6) of SEBI (LODR) Regulations, 2015

Please find enclosed herewith the Results Presentation for the Quarter and financial year ended March 31, 2025, for

your record.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Windlas Biotech Limited

Ananta Narayan Panda Company Secretary & Compliance Officer

Encl: as above

www.windlas.com

Windlas Biotech Limited Investor Presentation – May 2025

Safe Harbour

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Windlas Biotech Limited (the “Company”), have been prepared solely for

information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in

connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing

detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty,

express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This

Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this

Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively

forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions

that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international

markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and

expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks,

as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this

Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by

third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

Managing Director’s Message

“The Indian Pharmaceutical Market (IPM) registered a YoY growth of 8.4% in FY25, largely driven by price increases with volume growth of 0.4%. We are pleased to report another quarter of strong performance of revenue growth of 20% YoY for FY25 and 18% YoY in Q4FY25.

Mr. Hitesh Windlass

Our Generic Formulations CDMO vertical continued to benefit from new customer additions and a broader product portfolio. The Trade Generics & Institutional vertical maintained its growth momentum through wider market penetration and institutional engagement. The company continues to work towards the initiatives in the export vertical such as filing of numerous dossiers and entry into newer markets.

Our proactive investments in quality systems, infrastructure, and digital transformation continue to position us strongly with respect to Schedule M compliance. We have begun utilizing Plant-2 extension in Q4 FY25 which gives us the required room for growth in upcoming period. Our Injectable facility has been approved by several large customers and few Injectable products made by us have been commercialized by our CDMO as well as Trade Generics verticals. We continue to augment our manufacturing network through modernization and retrofit of our recently acquired Plant-6 oral solids facility as per plan.

The company achieved its highest-ever earnings per share (EPS) in FY25 (Rs 29.19) post listing. In line with our dividend policy, the company paid Rs 11.5 crores (Rs 5.5 per share) dividend related to FY24 and proposed the dividend of Rs 12.1 crores (Rs 5.8 per share) related to FY25.

Looking ahead, we remain focused on enhancing long-term value for shareholders through diversification of client- base, increasing operational efficiencies, retaining & rewarding of key talent and expansion of dosage forms.”

CEO & CFO's Message

“ We are pleased to conclude FY25 with strong performance across key metrics:

Rs 759 Cr. Revenue, 20.4% YoY growth 9th straight quarter of record revenue, Rs 202.7 Cr. (18.3%YoY growth) Highest ever EPS of Rs 29.19 post listing

• • • • Working Capital days 14 • •

Sustained ROCE & ROE > 20% alongside capacity expansion projects Strong liquidity Rs 213 Cr.

Ms. Komal Gupta

We have sustained our operating margins, reflecting our robust financial management despite an increase in depreciation, largely attributable to the Injectables facility and the Plant-2 extension. PAT stood at Rs. 61.0 crore for FY25 and Rs. 16.3 crore for Q4FY25 – as compared to Rs. 58.2 crore and Rs. 17 crore for FY24. EBITDA grew by 20% YoY to Rs. 94.1 crore for FY25, and by 16% YoY to Rs. 25.5 crore for Q4FY25.

India’s pharmaceutical industry ranks as the third-largest globally by volume. Our state-of-the-art manufacturing facilities in Dehradun strengthen our ability to deliver high-quality, scalable solutions to meet the evolving demands of the market. Windlas is strategically positioned to capture growth through diversified presence across its core verticals.

In Generic Formulations CDMO vertical we continue to direct our efforts towards sustained client engagement, new client acquisitions, new product launches and higher wallet share from current partners.. This vertical recorded 15% YoY increase in FY25 to Rs. 555.1 crore. For Q4FY25, this vertical generated Rs. 147.2 crore in revenue, witnessing 15% YoY growth.

Trade Generics and Institutional vertical is driven by portfolio expansion, broader distribution and institutional network, also supported by government driven initiatives. Our Trade Generics and Institutional vertical continued its growth momentum in FY25, with revenue surged to Rs. 172.1 crore, marking a 41% YoY increase. For Q4FY25, revenue increased to Rs. 45.5 crore, registering 31% growth YoY.

Exports vertical reported revenue of Rs. 32.6 crore in FY25, a 19% increase YoY, with Q4FY25 showing a revenue of Rs. 10.0 crore reflecting 12% growth YoY.

In conclusion, FY25 has been a year of meaningful progress for Windlas—anchored by consistent growth, resilient margins, and strategic execution. These results underscore the strength of our business fundamentals and the clarity of our vision. As we look ahead, we remain confident in our ability to seize emerging opportunities and deliver enduring value to all our stakeholders“

Financial Performance Highlights

Key Highlights: FY25

Revenue 760 Cr. YoY growth 20%

9th straight quarter of record revenue 203 Cr

EBITDA 94 Cr. YoY growth 20%

Highest ever EPS post listing 29.19

Cash generated from operations 68.2 Cr.

Working Capital days 14

ROCE*- 25% ROE* - 23%

Strong Liquidity 213 Cr. (Capex FY25 72 Cr.)

*For ROCE & ROE, Capital Employed & Equity at the end of period after removing cash/bank & mutual fund balances at the end of period

Annual Performance Highlights

Revenue

+20%

759.9

631.0

EBITDA & EBITDA Margin (%)

13.4% 11.3%

12.4%

11.2% 12.4%

Rs. Crores

Clocked in highest Clocked in highest ever annual Revenue ever annual Revenue & EBITDA & EBITDA

+20%

94.1

78.2

d e t a d

i l

o s n o C

FY24

FY25

FY24

FY25

Generic Formulations CDMO

+15%

555.1

481.2

Trade Generics & Institutional

+41%

172.1

122.4

Exports

+19%

32.6

27.4

e u n e v e R

a c i t r e V

FY24

FY25

FY24

FY25

FY24

FY25

Quarterly Performance Highlights

Revenue

+18%

202.7

171.3

EBITDA & EBITDA Margin (%)

13.4% 11.3%

12.8%

11.2% 12.6%

Rs. Crores

9th straight 9th straight quarter of record quarter of record revenue 203 Cr revenue 203 Cr

+16%

25.5

22.0

d e t a d

i l

o s n o C

Q4 FY24

Q4 FY25

Q4 FY24

Q4 FY25

Generic Formulations CDMO

+15%

147.2

127.6

e u n e v e R

a c i t r e V

Trade Generics & Institutional

+31%

45.5

34.7

Exports

+12%

10.0

8.9

Q4 FY24

Q4 FY25

Q4 FY24

Q4 FY25

Q4 FY24

Q4 FY25

Vertical Break-up

FY24

FY25

77%

19%

73%

23%

CDMO

Trade Generics & OTC

Exports

CDMO

Trade Generics & OTC

Exports

Q3FY25

Q4FY24

Q4FY25

25%

70%

CDMO Trade Generics & OTC Exports

75%

20%

73%

22%

CDMO Trade Generics & OTC Exports

Consolidated Profit & Loss Statement – Q4 & FY25

Particulars (Rs. Crores)

Net Revenue from Operations

COGS

Gross Profit

Gross Margin (%)

Employee Expenses

Other Expenses

EBITDA

EBITDA Margin (%)

Other Income

Finance Costs

Depreciation*

Reported PBT*

Taxes

Reported PAT*

FY25

759.9

471.9

288.0

37.9%

122.9

71.0

94.1

12.4%

18.0

4.4

28.0

79.8

18.8

61.0

FY24

631.0

396.2

234.8

37.2%

87.5

69.2

78.2

12.4%

13.5

1.1

13.4

77.1

19.0

58.2

YoY%

20.4%

22.7%

69bps

20.4%

0bps

3.5%

4.8%

Q4FY25

Q4FY24

202.7

125.2

77.5

38.2%

31.9

20.0

25.5

171.3

107.2

64.1

37.4%

22.8

19.3

22.0

12.6%

12.8%

4.9

1.3

8.3

20.8

4.5

16.3

4.4

0.3

3.5

22.6

5.6

17.0

YoY%

18.3%

20.9%

80bps

16.3%

-22bps

-7.8%

-4.0%

*Almost all incremental depreciation is attributable to new facilities (Injectable & Pl-2 extension).

Rewarding Shareholders

•

The highest ever earnings per share (EPS) post listing stood at Rs. 29.19 in FY25.

Dividend:

•

In line with our policy, Company proposed to pay the dividend of Rs 12.1 Cr (Rs 5.8 per share) to its shareholders for FY25 and paid

dividend of Rs 11.5 Cr (Rs 5.5 per share) related to FY24.

According to our company policy, we aim to maintain a Dividend Payout Ratio as near as possible to 20% of our consolidated profit after

tax, subject to -

o Company’s need for Capital for its growth plan

o Positive Cash Flow

EPS

Dividend (Rs. In cr.)

28.0

29.2

11.5

12.1

18.6

19.7

16.0

8.9

7.6

5.5

FY20

FY21*

FY22

FY23

FY24

FY25

FY20

FY21

FY22

FY23

FY24

FY25**

*Adjusted for exceptional items in FY21 (Negative Impact of Rs. 22 Crs) **Proposed dividend for the financial year ended March 31, 2025, which shall be payable subject to the approval of shareholders at the ensuing Annual General Meeting (“AGM”) of the Company

Company Overview

Windlas Biotech at Glance

Scalability

Durability

Profitability

 5 year CAGR :-

• Revenue – 18% • EBITDA – 23% • PAT – 30%

 Leading Domestic Generic Formulations CDMO

in terms of Revenue

 Provided Generic Formulations CDMO products services to 7 of the Top 10 (15 of top 20) Indian Pharmaceutical Formulations Companies (in FY25)

 Commissioned State-of-the-Art Injectable

facility. Increased OSD capacity through Plant-2 extension.

 Well aligned workforce with ESOPs and

 Revenue FY25 Rs 759.9 crores

variable pay

 Digitalized Planning and Quality

Management Systems with Data Analytics based decision support

 Emphasis on Chronic and Sub-chronic therapies (60%) and Complex Generics (67%) (for FY25)

 Own R&D Labs High innovation velocity - Complex products grown from 3,190 to 4,340 in FY25 vs FY24

 Strong Liquidity of INR 213 Crores as on

FY25 and Net Debt Free Company.

 EBITDA stood at INR 94.1 crores for FY25

with 12.4% EBITDA margin

 PAT# of INR 61.0 crores for FY25 with 8.0%

PAT margin

 RoCE** – 25% and RoE** – 23% For FY25

 Generated net operating cashflows of Rs.

68.2 Cr during FY25

 Working capital days at 14

# PBT and PAT include incremental depreciation majorly attributable to Injectable facility. *from the State Drug Licensing Authority, Drug Controlling and Licensing Authority (Manufacturing), Garhwal Mandal, Uttarakhand ** For ROCE & ROE, Capital Employed & Equity at the end of period after removing cash/bank & mutual fund balances at the end of period

Windlas Biotech’s Presence in Pharma Value Chain

Innovator Value Chain

Patent Expiry

Research

Clinical trials (I-III)

Bulk Drugs Manufacturing

Formulation Manufacturing

Marketing

Value Chain

Generics API dev & Manufacturing

Formulation dev & Manufacturing

Clinical (III+ )

Packaging

Marketing

Generic Value Chain

Windlas is present in all segments of Generics Value chain

#Windlas focus is on formulation, development, manufacturing and marketing

We invest in creating our own formulation technology for our products. Almost 100% of our CDMO supplies are based on products where we own the entire IP from initiation to regulatory permission.

Journey So Far…

 Commenced operations at

Dehradun Plant – I and initiated commercial production

Dehradun Plant – IV Revenues crossed INR 100 Crores for FY2010

 Received first USFDA inspection clearance  Revenues crossed ₹200 Crores for the FY

• Revenues crossed ₹300 Crores for the FY 2016-17 • Launched first product in the United States from

2013-14

the Dehradun Plant – IV

 Commenced operations at Plant – II  Investment of ₹75 Crores from Tano India

• Commenced operations at Dehradun Plant – III • Divestment of Windlas Healthcare to Cadila

Private Equity Fund II

Healthcare

2001

2010

2014-15

2018

2025

2023-24

2021-22

2019-20

 Revenues crossed ₹750 Crores for the

FY25

 Injectable facility GMP certified  Completed Plant 2 extension  Initiated Pl-6 capex for OSD capacity

expansion

 Plant-IV approved by SAPHRA(South

 Got listed on Exchanges in

Africa) and EU-GMP(Europe)

 Commissioned Plant-V Injectable facility

August 2021

 Capacity of Capsules/ Tablets

increased from 5 Bn+ as of Mar 31,2020 to 7 Bn+ as of March 31, 2022

 Invested ₹89 Mn in building Plant and Machinery  Acquired the erstwhile associate – Windlas

Healthcare(Now Plant-IV)

Strong Board of Directors…

 Ex Chairman of Confederation of Indian Industries , Uttarakhand State Council,  Established Windlas Biotech in 2001.  Led Windlas Biotech as MD till 2020

 24+ years of experience in the

pharmaceutical industry, he has a Bachelor’s degree in Law from the Hemwati

 Nandan Bahuguna Garhwal University,

Srinagar (Garhwal)

Pawan Sharma Executive Director

23+ years of experience in field of management Bachelor’s degree from the IIT-BHU, MS in Material Science & Engr. from Georgia Institute of Technology and MBA from the Booth School of Business, University of Chicago Leads the company since 2008

 22+ years of experience.  Bachelor’s degree in technology from the IIT, Delhi, Master’s degree in science from University of Southern California, and an MBA from University of Chicago.

 Currently associated with Michael & Susan Dell Foundation India and previously with Boston Consulting Group

Prachi Jain Windlass Non-Executive Director

Co-founded Windlas Biotech in 2001 Deeply engaged in managing client relations, and product portfolio expansion Plays a significant role in driving the product portfolio decisions and overall commercial operations including business development, supply chain and procurement He is a BBA graduate from George State University Atlanta

Gaurav Gulati Independent Non-Executive Director

 Bachelor’s degree in Science (computer

science) from the University of Illinois. MBA from Booth School of Business.

Ashok Kumar Windlass Whole Time Director

Hitesh Windlass Managing Director

Manoj Kumar Windlass Jt. Managing Director



 



Vivek Dhariwal Chairman and Independent Director

 24+ years of experience in manufacturing and supply operations.

 Previously associated with ICI India Ltd, Baxter India Private Ltd, and Pfizer Ltd.

 Bachelor’s degree from IIT-B &

Master’s degree in science from University of Kentucky

Srinivasan Venkatraman Independent Non-Executive Director

 Fellow member of the Institute of Chartered Accountants of India.  Previously associated with Wealth Tree Advisors, Hines, Aon Global Insurance Services, and Lovelock & Lewes

…Coupled with Proficient Management Team

Ms. Komal Gupta, CEO & CFO • Experience – 20+ Years; • Educational Qualification - CA, CS & CWA • Working with Windlas since 2015 •

Previously worked with DSM Group and Anand Automotives Systems Ltd.

Mr. Ananta Narayan Panda, Company Secretary and Compliance Officer • Experience - 24+ Years; • Previously worked with GMR Airports Limited, Spice Smart Solutions Limited

Mr. Om Prakash Sule, Site Quality Head • •

Experience - 28+ Years; Previously worked with Piramal Enterprises Limited and Mankind Pharma Limited.

Mr. Mohammed Aslam, President – Sales and Marketing • Experience - 45+ Years; • Educational Qualification - Graduate in Science (Biology &

Chemistry) Previously worked with Pharmed -Bracco, Modi-Mundi Pharma, a Swiss MNC and Dalmia Industries Limited

Vertical Overview

Generic Formulations CDMO

Trade Generics & Institutional

Exports



Generic Formulations CDMO vertical focused on providing products & services across- a diverse range of pharmaceutical & nutraceutical generic products. ‘Marketeers’ equally responsible for quality of the drug product in eyes of regulator New schedule M implemented in October 2021 – many small manufacturers may become unviable Such products are sold to Indian or foreign Pharma MNCs who market products under their own brand names. Intellectual Property Rights of 99% of products sold owned by Windlas.



This vertical consists of Trade Generics which includes products sold to various institutions. These products are Drugs for which Patents have been expired and are typically used as a substitute to branded expensive Generic medicines. Generally sold to the Distributors & not Medical representatives.



Export vertical is engaged in identifying high growth opportunities in Semi regulated international markets & selected regulated markets. The motive is to Develop & Register product applications in order to obtain marketing authorizations for medicines & health supplements. Subsequently such products are sold to Pharmaceutical & Pharmacies in the respective markets.

Companies

Contribution as a % of Total Revenue from Operations

88%

86%

83%

78%

77%

73%

18%

19%

23%

10%

13%

FY20

FY21

FY22

FY23

FY24

FY25

FY20

FY21

FY22

FY23

FY24

FY25

FY20

FY21

FY22

FY23

FY24

FY25

Generic Formulations CDMO Business Highlights

No. Of Customers 757

No. of Brand Catered (Brand ownership with customers) 5,582

Products Fixed dosage, Fixed dosage plus modified release, Customized generics, chewable/ dispersible and plain oral solids

Revenue Mix (% of FY25) 73%

Amongst the leading Domestic Generic Formulations CDMO in India

Intellectual Property Rights of 99% of products sold owned by Windlas

Well Diversified Product Portfolio

Windlas provides Generic Formulations CDMO products & services ranging from product discovery, product development, licensing and commercial manufacturing of complex generic products in compliance with current GMP

Company’s product portfolio predominantly overlaps with Fast Growing Chronic vertical and High Margin Complex Generic Vertical:

Generic Formulations CDMO Revenue grew with a CAGR of 14%

Value chain of End-to-end Services

Portfolio Bifurcation as % of Total Revenue from Operations FY25

INR Crores

41%

33%

+14%

365

384

403

288

555

481

Product Discovery & Development

59%

FY20

FY21

FY22

FY23

FY24

FY25

67%

CDMO Revenue

Licensing

No. of Generic Formulations CDMO Products Catered every year

Chronic & Sub-Chronic Acute

Complex Generics Conventional Products

+40%

4,273

5,582

(i) chronic and sub-chronic, such as, anti-diabetic, cardiovascular, neuropsychiatry, respiratory health and nutraceuticals ; and (ii) acute, such as, gastroenterology, vitamins, minerals and supplements (“VMS”), analgesic, dermatological and cough/ cold

1,051

1,364

2,771

1,834

2020

2021

2022

2023

2024

2025

Contract Manufacturing

Large Marquee Customer Base

 Streamlined Client Acquisition Process

Added New Customers at a rapid pace

Lead Identification

Proposal Creation

Negotiation

Contract Winning

Client Management

 Key Factors that lead to Expansion of Customer base

Audits by several MNC & Domestic Customers over the years

Product Excellence : dosage innovation, developing complex generic products

Manufacturing Excellence : track record, responsiveness, quality & technical standards, turnaround times

Planned capital expenditure: Invested in specialized products and services and equipment and dedicated infrastructure

 Key Factors that lead to Expansion of Customer base

 Quality, Quantity and specifications for the products

 Company is responsible for the procurement of raw materials and packaging

materials

 Provide the proper pricing & supply terms

757

+40%

583

441

143

204

285

FY20

FY21

FY22

FY23

FY24

FY25

No. of CDMO Customers catered to

Key Highlights

We have consistently maintained strong, exclusive & Long-Standing relationships with the leading Indian Pharmaceutical companies.

Provided Generic Formulations CDMO Products and Services to 7 of the top 10 (15 of the top 20) Indian Formulations pharmaceutical companies.

De-Risking the Customer Concentration

Long-term nature of the relationships help in pre-plan the Capex and eventually help in achieving sustainable growth and profitability

Long-term Relationships with Marquee Clients

Ease is Pre-Planning Capex

Increased Economies of Scale

Strengthened Purchasing Power for Raw Materials

Competitive cost structure in order to achieve Profitability

Continuously reducing highest customer’s contribution

Lowering client concentration risk

11.7%

11.0%

12.6%

56.8%

57.5%

51.9%

9.5%

8.7%

6.1%

42.0%

35.5%

34.4%

2020

2021

2022

2023

2024

2025

2020

Top Customer Contribution

2021

2022

2024 Top 10 Customers Contribution

2023

2025

Domestic Trade Generics & Institutional Business Overview

Brand Ownership is with Windlas Company’s Brand Names

Products Focus on Respiratory, Anti-diabetic, Gastroentology & other chronic + sub chronic TA’s

Revenue Mix (% of FY25) 23%

No. of Brands 400

Leveraging Trade Generics & Institutional Market Opportunity

Highlights

Key Drivers

Fastest Growing SBV in the last three years chart

Rs. 172 Crores Trade Generics & Institutional SBV revenue (FY25)

Low costs generics

compared to branded

Distributed through 1,095 Stockists & Distributors spread across 29 states (FY25)

Similar quality to branded generics but are sold at relatively lower prices

Sold directly to the distributor and not marketed through Medical representatives.

People in rural areas who are less privileged to access the healthcare facilities

INR Crores

Trade Generics & Institutional Revenue

172

+42%

122

FY20

FY21

FY22

FY23

FY24

FY25

With number of Brands on growing at a healthy pace

+26%

271

280

400

Also includes institutional sales.

Government push for schemes such as Jan Aushadhi Yojana, encouraging traded generics use

185

218

128

FY20

FY21

FY22

FY23

FY24

FY25

Export Business Overview

No. Of Customers Focused on Emerging & Semi-Regulated Markets

Brand Used Own Brands and End Customer Brands

Products Exported 80 Products during FY25 which includes Generic Medicines & Health Supplements

Revenue Mix: 4% of FY25 Revenue from Operations Exports SBV: INR of 33 crore as of FY25.

Geographic Reach

Robust R&D Capabilities

Robust R&D capabilities help in Customize and Market Complex; Generic Products to Customers and differentiate from Competition

R&D Key Highlights

Consistent in R&D Expenditure

Robust Growth in Complex Generics

R&D Expenditure

No. of Variations in Complex Generics

INR Crores

DSIR approved state of the art R&D laboratory & pilot scaled equipments

Focus on low cost First-to-launch generic products

Fully staffed formulation and analytical development, medical affairs and regulatory teams

3.9

3.6

8.9

7.9

6.5

6.3

2020

2021

2022

2023

2024

2025

Leading to New Innovations

+43%

3,190

4,340

725

934

1,901

1,325

2020

2021

2022

2023

2024

2025

Leading to Significant increase in Revenue from High Margin Complex Generics:

Significant Experience in developing Multi-Drug Products

Medicated chewing gum (multi-vitamin)

Chocolate flavored chewable tablets

Dispersible tablets

Sustained release products

Novel Formulations of Existing Molecules

29%

33%

28%

11%

24%

12%

35%

25%

12%

30%

32%

26%

27%

28%

29%

32%

7% 1%

38%

7% 1%

35%

33%

Fixed Dosage Combinations

Fixed Dosage Modified Release

Customised Generics

Chewable/ Dispersable

Plain Oral Solids

FY20

FY21

FY22

FY23

FY24

FY25

Competencies in Manufacturing Facilities

Efficiency & Effectiveness in Regulatory & Quality Compliance act as solid Entry Barriers

Dehradun Plant 1 commenced operations in 2001

Dehradun Plant 2 commenced operations in 2014

Dehradun Plant 3 commenced operations in 2018

Dehradun Plant 4 commenced operations in 2009

Dehradun Plant 5 commenced operations in 2024

Total Installed operating capacity per annum

Plant wise operating capacity as of 31st March FY25

Key Highlights

Windlas Biotech Limited has informed the Exchange about Investor Presentation

Market Movers